BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23108642)

  • 1. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
    Domingos H; Cunha RV; Paniago AM; Souza AS; Rodrigues RL; Domingos JA
    Arq Bras Cardiol; 2012 Nov; 99(5):997-1007. PubMed ID: 23108642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience].
    Bottaro EG; Caravello O; Scapellato PG; Stambulian M; Vidal GI; Loggia V; Scapellato JL; Thompson F; Cassetti I
    Enferm Infecc Microbiol Clin; 2008; 26(6):325-9. PubMed ID: 18588813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
    De Hert M; Kalnicka D; van Winkel R; Wampers M; Hanssens L; Van Eyck D; Scheen A; Peuskens J
    J Clin Psychiatry; 2006 Dec; 67(12):1889-96. PubMed ID: 17194266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are HIV positive patients resistant to statin therapy?
    Johns KW; Bennett MT; Bondy GP
    Lipids Health Dis; 2007 Oct; 6():27. PubMed ID: 17958912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Tselepis AD; Elisaf MS
    Lipids; 2011 Jun; 46(6):521-8. PubMed ID: 21327725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin: a review of its use in the management of dyslipidemia.
    Scott LJ; Curran MP; Figgitt DP
    Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
    Gómez-García A; Martínez Torres G; Ortega-Pierres LE; Rodríguez-Ayala E; Alvarez-Aguilar C
    Rev Esp Cardiol; 2007 Dec; 60(12):1242-9. PubMed ID: 18082089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
    Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease].
    Szapáry L; Fehér G
    Orv Hetil; 2012 Jun; 153(22):857-60. PubMed ID: 22641260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.